Assessing Patient Perception of Risk in Ocular Stem Cell Therapies

Scientists assessed risk tolerance using an in-person survey of 178 patients at an academic eye center. Risk of malignancy served as a hypothetical, readily understood, and serious adverse event to be considered in trade for potential visual improvement from a stem cell-derived treatment.
[Stem Cell Reports]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Novel TCR-like CAR-T Cells to Target an HLA*0201 Restricted Epitope from the Cancer-Testis Antigen SSX2 Display Strong Activity against Acute Myeloid Leukemia

Researchers developed a T cell receptor-like antibody that binds Synovial Sarcoma X breakpoint 2 (SSX2) peptide 41-49 in the context of HLA-A*-0201.
[Molecular Therapy-Methods & Clinical Development]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

B Cell Depletion Abrogates Immune Mediated Cytopenia and Rejection of Cord Blood Transplantation in Hurler Syndrome

Researchers studied 57 patients in two centers who received myeloablative conditioning for cord blood transplant in Hurler syndrome, and reported a significant improvement in event-free survival with reduced incidence of graft failure and without any evidence of immune-mediated cytopenia in those patients that had received rituximab.
[Bone Marrow Transplantation]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Maintenance Therapy after Second Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: A CIBMTR Analysis

Scientists explored the effect of maintenance therapy on outcomes after salvage second autologous hematopoietic cell transplant using the Center for International Blood and Marrow Transplant Research registry.
[Bone Marrow Transplantation]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

PI3Kγδ Inhibitor plus Radiation Enhances the Antitumor Immune Effect of PD-1 Blockade in Syngenic Murine Breast Cancer and Humanized Patient-Derived Xenograft Model

Murine breast cancer cells were grown in both immune-competent and -deficient BALB/c mice, and tumors were irradiated by three fractions of 24 Gy. A PD-1 blockade and a phosphoinositide 3-kinase (PI3K)γδ inhibitor were then administered every other day for two weeks.
[European Journal of Cancer]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Genome Editing in Large Animal Models

Large animal models, including dogs, pigs and non-human primates, bear greater resemblance to human anatomy, immunology and lifespan, and can be studied over longer timescales with clinical dosing regimens that are more relevant to humans.
[Molecular Therapy]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
AbstractGraphical Abstract
Bookmark

No account yet? Register

Share

A Phase I/II Dose-Escalation Multi-Center Study to Evaluate the Safety of Infusion of Natural Killer Cells or Memory T Cells as Adoptive Therapy in Coronavirus Pneumonia and/or Lymphopenia: RELEASE Study Protocol

In the Phase I trial, 18 patients with COVID-19-related pneumonia and/or lymphopenia with no oxygen requirement or with an oxygen need of less than or equal to 2.5 liters per minute in nasal cannula were assigned to two arms, based on the biology of the donor and the patient.
[Trials]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Atara Biotherapeutics and Pierre Fabre Enter Strategic Collaboration to Commercialize Tabelecleucel (Tab-Cel®)

Atara Biotherapeutics, Inc. and Pierre Fabre announced an exclusive commercialization agreement for tabelecleucel in Europe, Middle East, Africa, and other select emerging markets for Epstein-Barr virus-positive cancers.
[Atara Biotherapeutics, Inc.]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

US FDA Approves Kite’s Tecartus® as the First and Only CAR T for Adults with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia

Kite, a Gilead Company announced the FDA has granted approval for Tecartus® for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
[Kite]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Stem Cells from Human Exfoliated Deciduous Teeth Affect Mitochondria and Reverse Cognitive Decline in a Senescence-Accelerated Mouse Prone 8 Model

SHEDs were cultured in vitro and injected into AD SAMP8 mice by caudal vein, and SHEDs labeled via synthetic dye showed in vivo migration to the head.
[Cytotherapy]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Outcomes and Toxicity of Allogeneic Hematopoietic Cell Transplantation in Chronic Myeloid Leukemia Patients Previously Treated with Second-Generation Tyrosine Kinase Inhibitors: A Prospective Non-Interventional Study from the Chronic Malignancy Working Party of the EBMT

Scientists presented the results of a prospective non-interventional study performed by the EBMT on 383 consecutive chronic myeloid leukemia patients previously treated with dasatinib or nilotinib undergoing allogeneic hematopoietic cell transplantation from 2009 to 2013.
[Bone Marrow Transplantation]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share
Share